Physician profile
Peter J Kobes
NPI 1447222690
$7,900.02
in general payments reported to CMS, 2019-2025
39 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,162 · 2020: $445 · 2021: $37.59 · 2022: $854 · 2023: $1,396 · 2024: $1,755 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,246 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,245.62 |
| Education | $155.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,317.75 | 2019-2025 | |
| Janssen Biotech, INC. | $758.18 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $716.15 | 2019-2024 | Trulance, Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $519.87 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $451.92 | 2019-2025 | |
| Genzyme Corporation | $320.28 | 2022-2025 | |
| Ardelyx, INC. | $263.56 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $245.17 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $206.66 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $194.71 | 2024-2025 | Vowst |
| Allergan, INC. | $162.47 | 2019 | |
| Intercept Pharmaceuticals, INC. | $161.39 | 2019-2023 | Ocaliva |
| Qol Medical, LLC | $157.67 | 2019-2025 | Sucraid |
| Madrigal Pharmaceuticals | $146.68 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $126.09 | 2019-2023 | Sutab |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $117.98 | 2024-2025 | Dupixent |
| Boston Scientific Corporation | $115.02 | 2023-2024 | Apollo Esg System, Resolution 360 Clip |
| Organon LLC | $107.06 | 2023-2025 | Hadlima |
| Daiichi Sankyo INC. | $93.62 | 2022-2024 | Injectafer |
| Shionogi INC | $92.84 | 2019 | |
| Lilly USA, LLC | $86.54 | 2024-2025 | Omvoh |
| Mallinckrodt Hospital Products INC. | $59.03 | 2025 | Terlivaz |
| Celltrion USA INC. | $56.28 | 2023-2024 | Zymfentra, Yuflyma |
| Ucb, INC. | $52.72 | 2019 | |
| Merck Sharp & Dohme LLC | $45.85 | 2022-2023 | Dificid |
| Romark Laboratories, Lc | $43.04 | 2019 | |
| Sandoz INC. | $38.01 | 2022-2024 | Hyrimoz |
| Nestle Healthcare Nutrition INC. | $32.35 | 2022 | |
| Celgene Corporation | $32.23 | 2022 | |
| Covidien LP | $27.41 | 2019 | |
| Endo Pharmaceuticals INC. | $25.58 | 2019 | |
| Ferring Pharmaceuticals INC. | $21.72 | 2024 | Rebyota |
| Amgen INC. | $20.72 | 2022 | |
| Heron Therapeutics, INC. | $17.01 | 2023 | Zynrelef |
| Ironwood Pharmaceuticals, INC | $15.61 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.27 | 2023 | Cyltezo |
| Alnylam Pharmaceuticals INC. | $12.70 | 2020 | |
| Intra-Sana Laboratories | $12.63 | 2022 | |
| Redhill Biopharma INC. | $12.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kobes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.